Formosa Pharmaceuticals Signs Non-Binding Terms Agreement With Eyenovia To Co-Develop Clobetasol Propionate Ophthalmic Suspension For Dry Eye Disease Relief
Portfolio Pulse from Benzinga Newsdesk
Formosa Pharmaceuticals has signed a non-binding terms agreement with Eyenovia to co-develop Clobetasol Propionate Ophthalmic Suspension for the relief of dry eye disease.
August 07, 2024 | 12:01 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eyenovia has entered into a non-binding terms agreement with Formosa Pharmaceuticals to co-develop Clobetasol Propionate Ophthalmic Suspension for dry eye disease relief.
The partnership with Formosa Pharmaceuticals to develop a new treatment for dry eye disease could potentially expand Eyenovia's product portfolio and market reach, positively impacting its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100